{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:19:18Z","timestamp":1793855958400,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014929","name":"Anthera","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014929","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jhep.2021.10.018","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T23:10:48Z","timestamp":1635894648000},"page":"506-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study"],"prefix":"10.1016","volume":"76","author":[{"given":"Vlad","family":"Ratziu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4234-224X","authenticated-orcid":false,"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Denham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeid","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-6474","authenticated-orcid":false,"given":"Aasim","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-3652","authenticated-orcid":false,"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taddese","family":"Desta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"DeGrauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Adda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jhep.2021.10.018_bib1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.018_bib2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.018_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.11648\/j.ijg.20190301.12","article-title":"Characterization of EDP-305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis","volume":"3","author":"Chau","year":"2019","journal-title":"Int J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jhep.2021.10.018_bib4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A\u00a0novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jhep.2021.10.018_bib5","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1096\/fj.201801699R","article-title":"The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction","volume":"33","author":"Li","year":"2019","journal-title":"Faseb J"},{"issue":"7","key":"10.1016\/j.jhep.2021.10.018_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep4.1193","article-title":"Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist","volume":"2","author":"Erstad","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.10.018_bib7","doi-asserted-by":"crossref","first-page":"S584","DOI":"10.1016\/S0168-8278(18)31427-2","article-title":"Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects","volume":"68","author":"Ahmad","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.10.018_bib8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","article-title":"Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.10.018_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2017.12.001","article-title":"A\u00a0critical review of endpoints for non-cirrhotic NASH therapeutic trials","volume":"68","author":"Ratziu","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.018_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.10.018_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2019.09.018","article-title":"Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis","volume":"72","author":"Bril","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.018_bib12","doi-asserted-by":"crossref","first-page":"575843","DOI":"10.3389\/fendo.2020.575843","article-title":"Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.jhep.2021.10.018_bib13","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.10.018_bib14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10215","key":"10.1016\/j.jhep.2021.10.018_bib15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.10.018_bib16","article-title":"A\u00a0structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"10","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2021.10.018_bib17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/10715762.2011.564164","article-title":"Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of gamma-glutamyltransferase expression","volume":"45","author":"Ravuri","year":"2011","journal-title":"Free Radic Res"},{"key":"10.1016\/j.jhep.2021.10.018_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12986-016-0097-7","article-title":"Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study","volume":"13","author":"Ali","year":"2016","journal-title":"Nutr Metab (Lond)"},{"issue":"2","key":"10.1016\/j.jhep.2021.10.018_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2008.10.052","article-title":"Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population","volume":"136","author":"Ruhl","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.018_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"issue":"10213","key":"10.1016\/j.jhep.2021.10.018_bib21","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.018_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"10165","key":"10.1016\/j.jhep.2021.10.018_bib23","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jhep.2021.10.018_bib24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.jhep.2021.10.018_bib25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.018_bib26","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"issue":"9972","key":"10.1016\/j.jhep.2021.10.018_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid\u00a0for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.018_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.018_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: how are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.10.018_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2021.10.018_bib31","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J\u00a0Lipid Res"},{"issue":"1","key":"10.1016\/j.jhep.2021.10.018_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2021.10.018_bib33","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.10.018_bib34","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A\u00a0randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"8","key":"10.1016\/j.jhep.2021.10.018_bib35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jhep.2021.10.018_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1194\/jlr.M400292-JLR200","article-title":"Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling","volume":"46","author":"Anisfeld","year":"2005","journal-title":"J\u00a0Lipid Res"},{"issue":"3","key":"10.1016\/j.jhep.2021.10.018_bib37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:01Z","timestamp":1759174981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821021553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0168827821021553"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}